MICROSCOPIC POLYANGIITIS
Clinical trials for MICROSCOPIC POLYANGIITIS explained in plain language.
Never miss a new study
Get alerted when new MICROSCOPIC POLYANGIITIS trials appear
Sign up with your email to follow new studies for MICROSCOPIC POLYANGIITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Study tests cheaper copycat drug for serious autoimmune disease
Disease control CompletedThis study aimed to see if newer, more affordable 'biosimilar' versions of the drug rituximab work as well and are as safe as the original version for patients with two serious autoimmune diseases (GPA and MPA). Researchers followed 201 Canadian patients for two years, tracking t…
Matched conditions: MICROSCOPIC POLYANGIITIS
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Smart dosing vs. scheduled shots: a fight to keep a serious autoimmune disease at bay
Disease control CompletedThis study tested two different long-term treatment plans for patients with a serious autoimmune disease called ANCA-associated vasculitis, who were already in remission. The goal was to see which plan was better at preventing the disease from flaring up again. One plan gave ritu…
Matched conditions: MICROSCOPIC POLYANGIITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Trial tests new strategy to prevent Flare-Ups of devastating autoimmune disease
Disease control CompletedThis study tested whether the drug rituximab is better than the standard drug azathioprine at keeping two severe autoimmune diseases (Wegener's granulomatosis and microscopic polyangiitis) in remission. It involved 117 adults whose disease was under control after initial treatmen…
Matched conditions: MICROSCOPIC POLYANGIITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Mar 02, 2026 15:25 UTC
-
Common drug tested for hidden power against debilitating autoimmune symptoms
Symptom relief CompletedThis study tested whether a very low dose of an existing medication (naltrexone) could improve daily life for people with several types of vasculitis, a group of autoimmune diseases that cause blood vessel inflammation. The trial involved 60 adults whose disease was stable but wh…
Matched conditions: MICROSCOPIC POLYANGIITIS
Phase: PHASE2 • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Apr 03, 2026 14:42 UTC